Dataset Information

In-depth plasma proteomics of patients with suspected lung cancer (lung adenocarcinoma and non-cancer controls) with HiRIEF LC-MS/MS

ABSTRACT: Here, we present an in-depth proteomic profiling of pre-diagnostic plasma samples from 114 individuals with suspected lung cancer, including 57 patients diagnosed with stage III-IV lung adenocarcinoma (LUAD) and 57 non-cancer controls. Plasma samples were depleted of high-abundant proteins, and proteomic analysis was performed using high-resolution isoelectric focusing (HiRIEF) coupled with liquid chromatography tandem mass spectrometry (LC-MS/MS), with relative quantification by isobaric tandem mass tags (TMT16-plex).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Lung Adenocarcinoma

SUBMITTER: Noora Sissala

LAB HEAD: Janne Lehtiö

PROVIDER: PXD061144 | Pride | 2025-11-11

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	XC-LCP1-114_20200812_HFTo_TMT16_SetA_640ug_IPG3-10_10of20_fr02.raw	Raw
	XC-LCP1-114_20200812_HFTo_TMT16_SetA_640ug_IPG3-10_10of20_fr03.raw	Raw
	XC-LCP1-114_20200812_HFTo_TMT16_SetA_640ug_IPG3-10_10of20_fr04.raw	Raw
	XC-LCP1-114_20200812_HFTo_TMT16_SetA_640ug_IPG3-10_10of20_fr05.raw	Raw
	XC-LCP1-114_20200812_HFTo_TMT16_SetA_640ug_IPG3-10_10of20_fr06.raw	Raw

Items per page:

1 - 5 of 362

Publications

Comparative evaluation of Olink Explore 3072 and mass spectrometry with peptide fractionation for plasma proteomics.

Sissala Noora N Babačić Haris H Leo Isabelle R IR Cao Xiaofang X Forshed Jenny J Eriksson Lars E LE Lehtiö Janne J Fredolini Claudia C Åberg Mikael M Pernemalm Maria M

Communications chemistry 20251104 1

Plasma proteomics technologies are advancing rapidly, offering new opportunities for biomarker discovery and precision medicine. Direct comparisons of available technologies are needed to understand how platform selection affects downstream findings. We compared the performance of a peptide fractionation-based mass spectrometry method (HiRIEF LC-MS/MS) and the Olink Explore 3072 proximity extension assays on 88 plasma samples, analyzing 1129 proteins with both methods. The platforms exhibited co ...[more]

PMID: 41188494

Similar Datasets

Project description:Part I - SI-NET tumors High Resolution Isoelectric Focusing (HiRIEF) LC-MS and relative quantification by iTRAQ 8-plex was used to analyze 14 small intestinal neuroendocrine tumors (SI-NETs). The data was obtained from two separate TMT10plex sets and linked by a single internal pooled standard. The internal pooled standard was made by combining equal aliquots of the tryptic peptide mixtures from each of the 14 tissue samples. iTRAQ set1 was composed of 7 SI-NET samples, all from different individuals, and internal pooled standard labelled as follows: Channel 113 (sample Screen-1 with liver metastasis), Channel 114 (sample Screen-8 with liver metastasis), Channel 115 (sample Screen-3 with liver metastasis), Channel 116 (sample Screen-2 with liver metastasis), Channel 117 (sample Screen-5 no liver metastasis), Channel 118 (sample Screen-4 no liver metastasis), Channel 119 (sample Screen-10 no liver metastasis), Channel 121 (internal pooled standard). iTRAQ set2 was composed of 7 SI-NET samples, all from different individuals, and internal pooled standard labelled as follows: Channel 113 (sample Screen-7 with liver metastasis), Channel 114 (sample Screen-11 with liver metastasis), Channel 115 (sample Screen-13 with liver metastasis), Channel 116 (sample Screen-6 no liver metastasis), Channel 117 (sample Screen-12 no liver metastasis), Channel 118 (sample Screen-9 no liver metastasis), Channel 119 (sample Screen-14 no liver metastasis), Channel 121 (internal pooled standard). Part II - time course profiling in cell lines High Resolution Isoelectric Focusing (HiRIEF) LC-MS and relative quantification by TMT 10-plex was used to analyze cellular response to the neddylation inhibitor pevonedistat (MLN4924) at different timepoints in two SI-NET (small intestinal neuroendocrine tumors) cell lines. The data was obtained from two separate TMT 10-plex experiments. TMT set1 includes a time course experiment upon pevonedistat treatment of CNDT2 cells with harvests at 2h, 6h, 12h and 24h after treatment as well as of untreated control cells. Isobaric tag labelling of peptide samples with TMT10plex was used as follows. Biological duplicate controls (TMT channels 126, 127N), duplicate 2h (127C, 128N), duplicate 6h (128C, 129N), duplicate 12h (129C, 130N) and duplicate 24h (130C, 131) samples were employed. TMT set2 includes a time course experiment upon pevonedistat treatment of HC45 cells with harvests at 2h, 6h, 12h and 24h after treatment as well as of untreated control cells. Isobaric tag labelling of peptide samples with TMT10plex was used as follows. Biological duplicate controls (TMT channels 126, 127N), duplicate 2h (127C, 128N), duplicate 6h (128C, 129N), duplicate 12h (129C, 130N) and duplicate 24h (130C, 131) samples were employed.